Biotech | August 24, 2021
Pfizer to acquire Trillium Therapeutics
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The company plans to invest in technology, business development, product innovation, and development across India
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The company has strong product launches both in India and overseas
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Board declares interim dividend of Rs 2 per equity share
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
